H.C. Wainwright lowered the firm’s price target on Sage Therapeutics to $25 from $27 and keeps a Neutral rating on the shares as the firm is removing the MDD indication from its model based on management commentary to focus on a “PPD-only,” or postpartum depression, focus for Zurzuvae.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE:
- SAGE Therapeutics Stockholders Approve Employee Stock Plan
- SAGE Therapeutics Secures New Cambridge Headquarters Lease
- Sage Therapeutics price target raised to $22 from $20 at Truist
- Sage Therapeutics price target raised to $34 from $24 at Scotiabank
- Sage Therapeutics price target raised to $30 from $26 at BofA
